Sclerotherapyprevention of accidents: a review' W A L MacGowan FRCSI FACS Royal College ofSurgeons in Ireland, Dublin Accidents from sclerotherapy are fortunately rare. They are rarely reported and probably under-reported. For the scleroseur accidents can be embarrassing, professionally damaging and costly. For the patient, likewise, they are costly and damaging, but also disabling or even life-threatening for a relatively trivial complaint. The accidents that occur with sclerotherapy can be divided conveniently into those associated with the sclerosant and those associated with the technique of injection.
Sclerosant
Vasovagal orfainting attacks: These are not uncommon following any injection and probably occur in about one in 100 patients (Winstone 1971) . The main hazard is that the patient may fall and cause injury. Appropriate precautions should therefore be taken with a nervous patient.
Allergic and anaphylactic reactions: These are fortunately less common, probably 2 in 1000 patients being affected (Winstone 1971) , and only one fatality has been recorded in over one million treated patients (R N Gardiner, STD Pharmaceutical Products, personal communication 1983). These reactions are usually the result of sensitivity to the sclerosant or overdosage, using more than 5 ml of sclerosant per sitting. Patients with a past history of allergy or past history of reaction to sclerotherapy should be considered 'high risks'. Changing the sclerosant or abandoning sclerotherapy for surgical or more conservative measures should be considered.
It is prudent to have readily available, during injection, an antihistamine like Piriton (chlorpheniramine maleate) and also adrenaline, steroid, salbutamol, inotropic drugs and intravenous infusion. Back-up cardiopulmonary support is rarely necessary but comforting, and is one of the advantages of sclerotherapy clinics being sited in or near general hospitals. Since most of these reactions occur within 30 minutes of injection, it is wise to keep the patient under observation for that period.
Toxic reactions: These are rare if the dose of sclerosant is kept under 5 ml per sitting. The symptoms are shivering, loin pain, discoloured urine, probably due to absorption of excess quantities of the sclerosant and altered blood into the general circulation (MacGowan et al. 1972 ).
Accidents resulting from injection technique
The commonest problem is injecting the sclerosant extravascularly, and if more than 0.5 ml is injected tissue necrosis can occur resulting in skin blistering, a plaque or an ulcer at the site of the extravasation. To prevent this accident, care should be taken with the vein stab and in using firm fixation of the needle and syringe when moving the limb to the elevated position. Great care should be taken during actual injection and if in doubt and causing discomfort the injection should be stopped. A minor degree of leakage occurs in one in 30 injections (Winstone 1971) , but this can usually be controlled by adequate compression and adverse tissue reaction reduced to a minimum or prevented. Venous thrombosis and ascending phlebitis: The incidence is approximately one in 1000 patients (Winstone 1971) . This complication should be considered in patients with high risk factors, such as obesity, cardiac disease, past history of thromboembolism and oral contraceptives. It is more likely to follow sclerotherapy when venous dilatation and incompetence extends up to the groin, particularly when associated with a saphena varix. There is a case for a prophylactic groin or saphenofemoral tie with these patients. In prevention, particular care should be paid to the 'empty vein' technique and not more than 0.5-1 ml of sclerosant should be injected. Finally, adequate compression bandaging and early ambulation reduce the risk of this complication.
Pulmonary embolism: The incidence is approximately 8 in 10 000 treated patients (Hadfield 1971) . Though no fatal cases have been reported, pulmonary embolism is probably more common than is suspected or reported. Patients at high risk should be identified, and prevention is similar to that already stated in relation to venous thrombosis. Consideration should be given to the use of prophylactic anticoagulants, efficient bandaging technique, supportive hose and early ambulation. Those patients considered to be at high risk for pulmonary embolism and venous thrombosis should be considered for alternative management, such as surgical interruption of the veins or more conservative management.
Accidental intra-arterial injection: The incidence is approximately one in 250 000 injections (Winstone 1971) . At least 5 cases have been reported to medical defence organizations. The author has had personal medicolegal experience of 2 patients, both of whom lost the distal part of the lower limb. The dangerous areas are near the post-tibial artery behind the medial malleolus, the anterior tibial artery in front of the ankle joint or, less probable, the popliteal artery behind the knee joint. Presumably the femoral artery is at risk in high groin injection.
This accident is recognized by the patient complaining of pain which is unusual in severity, tingling in the foot or a burning sensation during the injection. If these symptoms occur the injection should be stopped immediately. There is experimental evidence to suggest that flushing the involved vessel or the femoral artery with heparinized saline may be beneficial because the mixture of sclerosant and blood forms a sludge which becomes impacted in the distal small arteries (MacGowan et al. 1972) . Heparin should be administered to prevent secondary or retrograde thrombosis. An intravenous infusion of dextran can reduce blood viscosity and cause beneficial haemodilution. Sympathectomy or sympathetic block has also been used, but is of doubtful value. The lesson in prevention is to be very careful or better to avoid injecting sclerosant into veins near the major arterial vessels of the limb.
'Blow-back' phenomenon: This results from an injection of sclerosant into perforators in close proximity to an ulcer which may result in the worsening of the ulcer. Presumably this results from thrombosis of blood vessels in or around the ulcer leading to necrosis (Winstone 1971). Injection ofnerve: This probably occurs in about one in 1000 injections (Winstone 1971) . The nerves at risk are the saphenous, sural and musculocutaneous. It is recognized by the ensuing pain, paraesthesia and anaesthesia in the distribution of the affected nerve. This relatively minor complication can be avoided by reflecting on the positions of the cutaneous peripheral nerves when injecting sclerosant, particularly below the knee.
